Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1

Gene Therapy

Volumn 4, Issue 12, 1997, Pages 1322-1329

  Felzmann, T ^a,b   Ramsey, W J ^a   Blaese, R M ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Adenovirus; Costimulation; Cytokine; Gene therapy; Herpes simplex virus thymidine kinase

Indexed keywords

B7 ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE THERAPY; HERPES SIMPLEX VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; HERPES; MURINAE; SIMPLEXVIRUS;

EID: 0031437602     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300533     Document Type: Article

References (35)

1. Blankenstein T. Increasing tumor immunogenicity by genetic modification. Eur J Cancer 1994; 30A: 1182-1187.
2. Chen L, Ashe S, Bradey WA. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102
3. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
4. Stratford-Perricaudet LD et al. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1990; 1: 241-256.
5. Blaese RM et al. In situ delivery of suicide genes for cancer treatment. Eur J Cancer 1994; 30A: 1190-1193.
6. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
7. Ram Z et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53: 83-88.
8. Caruso M et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024-7028.
9. Ram Z et al. Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res 1994, 54: 2141-2145.
10. Oldfield EH, Ram Z, Chiang Y, Blaese RM. Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. GTI 0108. A phase I/II study. Hum Gene Ther 1995; 6: 55-85.
11. Klatzmann D. Gene therapy for metastatic malignant melanoma: evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidme kinase gene, to be followed by ganciclovir administration. Hum Gene Ther 1996; 7: 255-267.
12. Izquierdo M et al. Human malignant brain tumor response to herpes simplex thymidme kinase (HSVtk)/ganciclovir gene therapy. Gene Therapy 1996; 3: 491-495.
13. Richards CD et al. Adenovirus vectors for cytokine gene expression. Ann NY Acad Sci 1995; 762: 282-292.
14. Chen SH et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
15. Chen SH et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92: 2577-2581.
16. Chen SH et al Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996; 56: 3758-3762
17. O'Malley BW Jr et al. Combination gene therapy for oral cancer in a murine model. Cancer Res 1996; 56: 1737-1741.
18. Gansbacher B. Clinical application of immunostimulatory gene transfer Eur J Cancer 1994; 30A: 1187-1190.
19. Thompson CB. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation. Cell 1995; 81: 979-982.
20. Fearon ER et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response Cell 1990; 60: 397-403.
21. Gajewsky TF, Renauid L-C, Pel AV, Boon T. Costimulation with B7 1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J Immunol 1995; 154: 5637-5648
22. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
23. Sun WH, Kreisle RA, Phillips AW, Ershler WB. In vivo and in vitro characteristics of interleukin 6-transfected tumor B16 melanoma cells. Cancer Res 1992; 52: 5412-5415.
24. Mullen CA et al. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res 1992; 52: 6020-6024.
25. Progador A, Tzehoval E, Katy VE. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunophenotypic competence against parental melaslalic cells. Cancer Res 1992; 52: 3679-3686.
26. Schmidt W et al. Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA 1995; 92: 4711-4714.
27. Ram Z et al. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J Neurosurg 1994; 80: 535-540.
28. Lenschow DJ, Walunas XL, Bluestone JA. CD28/B7 system of T cells costimulation. Annu Rev Immunol 1996; 14: 233-258.
29. Larsen CP et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7.2) expression on murine dendritic cells. J Immunol 1994; 152: 5208-5219.
30. Wustrow TP, Issing WJ. Immune defects in patients with head and neck cancer. Anticancer Res 1993; 13: 2507-2519.
31. Tepper RJ, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503-512.
32. Graham FL, Smiley J, Russel WC, Nairn R Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-72.
33. Stephenson JR, Aaronson SA Antigenic properties of murine sarcoma virus-transformed BALB-3T3 nonproducer cells. J Exp Med 1972; 135: 503-515.
34. Aaronson SA, Weaver CA. Characterization of a murine sarcoma virus (Kirsten) transformation of mouse and human cells. J Gen Virol 1971; 13: 245-252.
35. Smith TA et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402